From: Concurrent chemoradiotherapy in adjuvant treatment of breast cancer
Characteristic | Group A [n = 110] No (%) | Group B [n = 134] No (%) | p value |
---|---|---|---|
Age | |||
   <40 | 31 (28.2%) | 23 (17.2%) | 0.039 |
   ≥40 | 79 (71.8%) | 111 (82.8%) |  |
Menopausal status | |||
   No | 75 (72.8%) | 77 (62.1%) | 0.087 |
   Yes | 28 (27.2%) | 47 (37.9%) |  |
Side | |||
   Right | 48 (43.6%) | 71 (53%) | 0.146 |
   Left | 62 (56.4%) | 63 (47%) |  |
Surgery | |||
   Mastectomy (Patey or Halsted) | 89 (80.9%) | 116 (86.6%) | 0.23 |
   Conservative | 21 (19.1%) | 18 (13.4%) |  |
Histology | |||
   DIC | 99 (94,3%) | 120 (90,9%) | 0.33 |
   LIC | 6 (5.7%) | 12 (9.1%) |  |
SBR | |||
   I | 6 (5.7%) | 11 (8.5%) | 0.567 |
   II | 69 (65.1%) | 87 (66.9%) |  |
   III | 31 (29.2%) | 32 (24.6%) |  |
Hormonal receptors | |||
ER | |||
   Positive | 77 (72%) | 97 (73.5%) | 0.793 |
   Negative | 30 (28%) | 35 (26.5%) |  |
PR | |||
   Positive | 61 (57.5%) | 82 (62.1%) | 0.474 |
   Negative | 45 (42.5%) | 50 (37.9%) |  |
Tumour | |||
   pT1 | 16 (14.7%) | 19 (14.5%) | 0.732 |
   pT2 | 62 (56.9%) | 76 (58%) |  |
   pT3 | 28 (25.7%) | 29 (22.1%) |  |
   pT4 | 3 (2.8%) | 7 (5.3%) |  |
pN, axillary | |||
   pN0 | 20 (18.2%) | 40 (29.9%) | 0.001 |
   pN1 | 30 (27.3%) | 42 (31.3%) |  |
   pN2 | 31 (28.2%) | 42 (31.3%) |  |
   pN3 | 29 (26.4%) | 10 (7.5%) |  |
Breast/thoracic wall irradiation | |||
   Yes | 109 (99.1%) | 124 (92.5%) | 0.014 |
   No | 1 (0.9%) | 10 (7.5%) |  |
Prophylactic supraclavicular fossa radiotherapy | |||
   Yes | 104 (94.5%) | 127 (94.8%) | 0.936 |
   No | 6 (5.5%) | 7 (5.2%) |  |
Internal mammary radiotherapy | |||
   Yes | 105 (95.5%) | 128 (95.5%) | 0.98 |
   No | 5 (4.5%) | 6 (4.5%) |  |
Axillary radiotherapy | |||
   Yes | 18 (16.4%) | 31 (23.1%) | 0.189 |
   No | 92 (83.6%) | 103 (76.9%) |  |